Treatments & Services

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.



  • IMMU-132 for Metastatic Urothelial Cancer

    A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)


  • Post-Mastectomy/Lumpectomy Radiation after Neoadjuvant Chemotherapy

    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy


Head and Neck



  • Canakinumab for Adjuvant Non-Small Cell Lung Cancer

    A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer




Solid Tumors

  • Cabozanitib +/- Atezolizumab in Solid Tumors

    A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

  • AVID100 in Patients with Advanced or Metastatic Solid Tumors

    A phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100. an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin

  • INCMGA00012 in Solid Tumors

    A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors

  • Febrile Neutropenia Observational Trial

    A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN

  • MGCD516 for Solid Tumor Malignancies

    A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies